AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 78-80 , February 2010

Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections

  • Cassandra Moran, DO

      Affiliations

    • Department of Pediatrics, Duke University School of Medicine, Durham, NC
    • ,
  • Chelsea A. Grussemeyer, BSPH

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC
    • ,
  • James R. Spalding, PharmD, MS

      Affiliations

    • Astellas Pharma US, Deerfield, IL
    • ,
  • Daniel K. Benjamin Jr., MD, MPH, PhD

      Affiliations

    • Department of Pediatrics, Duke University School of Medicine, Durham, NC
    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Shelby D. Reed, PhD

      Affiliations

    • Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham, NC
    • Department of Medicine, Duke University School of Medicine, Durham, NC
    • Corresponding Author InformationAddress correspondence to Shelby D. Reed, PhD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715.

References 

  1. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006;25:419–425
  2. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–1239
  3. Nolla-Salas J, Sitges-Serra A, León-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 1997;23:23–30
  4. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002;50:243–260
  5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
  6. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non- albicans candidemia in nonneutropenic patients. Ann Pharmacother. 2007;41:568–573
  7. Moran C, Grussemeyer CA, Spalding JR, Benjamin DK, Reed SD. Candida albicans and non- albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J. 2009;28:433–435
  8. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27:781–788
  9. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 2008;60:273–277
  10. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol. 2008;46:2222–2226

PII: S0196-6553(09)00755-X

doi: 10.1016/j.ajic.2009.06.014

AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 78-80 , February 2010

Article Tools